Stay updated with breaking news from Xiaoxu Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to r
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to new research.
Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.